Biotricity (BTCY) Stock Forecast, Price Target & Predictions
BTCY Stock Forecast
Biotricity stock forecast is as follows: an average price target of $4.00 (represents a 1493.63% upside from BTCY’s last price of $0.25) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BTCY Price Target
The average price target for Biotricity (BTCY) is $4.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $4.00. This represents a potential 1493.63% upside from BTCY's last price of $0.25.
BTCY Analyst Ratings
According to 1 Wall Street analysts, Biotricity's rating consensus is 'Buy'. The analyst rating breakdown for BTCY stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Biotricity Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 05, 2023 | Kevin Dede | H.C. Wainwright | $4.00 | $2.67 | 49.66% | 1493.63% |
The latest Biotricity stock forecast, released on Jul 05, 2023 by Kevin Dede from H.C. Wainwright, set a price target of $4.00, which represents a 49.66% increase from the stock price at the time of the forecast ($2.67), and a 1493.63% increase from BTCY last price ($0.25).
Biotricity Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.25 | $0.25 | $0.25 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Biotricity stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Biotricity's last price of $0.25. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 05, 2023 | H.C. Wainwright | Buy | Buy | Hold |
Biotricity's last stock rating was published by H.C. Wainwright on Jul 05, 2023. The company gave BTCY a "Buy" rating, the same as its previous rate.
Biotricity Financial Forecast
Biotricity Revenue Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $2.89M | - | $2.74M | $2.46M | $2.38M | $2.06M | $2.15M | $1.76M | $1.81M | $1.93M |
| Avg Forecast | $3.50M | $3.30M | $3.27M | $3.20M | $3.20M | $3.00M | $3.30M | $3.10M | $2.60M | $2.40M | $2.54M | $2.19M | $2.11M | $2.10M | $1.81M | $1.60M |
| High Forecast | $3.50M | $3.30M | $3.27M | $3.20M | $3.20M | $3.00M | $3.30M | $3.10M | $2.60M | $2.40M | $2.54M | $2.19M | $2.11M | $2.10M | $1.81M | $1.60M |
| Low Forecast | $3.50M | $3.30M | $3.27M | $3.20M | $3.20M | $3.00M | $3.30M | $3.10M | $2.60M | $2.40M | $2.54M | $2.19M | $2.11M | $2.10M | $1.81M | $1.60M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | 0.88% | - | 1.05% | 1.02% | 0.94% | 0.94% | 1.02% | 0.84% | 1.00% | 1.21% |
Biotricity's average Quarter revenue forecast for Dec 23 based on 1 analysts is $3.00M, with a low forecast of $3.00M, and a high forecast of $3.00M. BTCY's average Quarter revenue forecast represents a 3.76% increase compared to the company's last Quarter revenue of $2.89M (Sep 23).
Biotricity EBITDA Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | $-2.32M | - | $-2.23M | $-4.36M | $-4.47M | $-4.53M | $-5.15M | $-3.02M | $-6.52M | $-5.00M |
| Avg Forecast | $-3.32M | $-3.13M | $-3.10M | $-3.03M | $-3.03M | $-2.84M | $-3.13M | $-2.94M | $-2.46M | $-2.27M | $-2.39M | $-2.06M | $-1.98M | $-1.98M | $-1.70M | $-3.69M |
| High Forecast | $-3.32M | $-3.13M | $-3.10M | $-3.03M | $-3.03M | $-2.84M | $-3.13M | $-2.94M | $-2.46M | $-2.27M | $-2.39M | $-2.06M | $-1.98M | $-1.98M | $-1.70M | $-2.95M |
| Low Forecast | $-3.32M | $-3.13M | $-3.10M | $-3.03M | $-3.03M | $-2.84M | $-3.13M | $-2.94M | $-2.46M | $-2.27M | $-2.39M | $-2.06M | $-1.98M | $-1.98M | $-1.70M | $-4.43M |
| Surprise % | - | - | - | - | - | - | 0.74% | - | 0.90% | 1.92% | 1.87% | 2.20% | 2.60% | 1.53% | 3.84% | 1.36% |
undefined analysts predict BTCY's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Biotricity's previous annual EBITDA (undefined) of $NaN.
Biotricity Net Income Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | $-3.69M | - | $-4.69M | $-4.72M | $-4.86M | $-4.88M | $-5.62M | $-5.97M | $-11.71M | $-5.66M |
| Avg Forecast | $-2.47M | $-2.47M | $34.67M | $19.02M | $-8.10M | $-9.90M | $-7.65M | $-9.22M | $-12.15M | $-12.15M | $-6.59M | $-9.35M | $-8.50M | $-11.62M | $-11.90M | $-6.28M |
| High Forecast | $-2.47M | $-2.47M | $34.67M | $19.02M | $-8.10M | $-9.90M | $-7.65M | $-9.22M | $-12.15M | $-12.15M | $-6.59M | $-9.35M | $-8.50M | $-11.62M | $-11.90M | $-5.03M |
| Low Forecast | $-2.47M | $-2.47M | $34.67M | $19.02M | $-8.10M | $-9.90M | $-7.65M | $-9.22M | $-12.15M | $-12.15M | $-6.59M | $-9.35M | $-8.50M | $-11.62M | $-11.90M | $-7.54M |
| Surprise % | - | - | - | - | - | - | 0.48% | - | 0.39% | 0.39% | 0.74% | 0.52% | 0.66% | 0.51% | 0.98% | 0.90% |
Biotricity's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BTCY's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Biotricity SG&A Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | $3.49M | - | $3.08M | $4.78M | $4.88M | $4.88M | $5.92M | $3.65M | $5.68M | $4.66M |
| Avg Forecast | $11.39M | $10.74M | $10.63M | $10.42M | $10.41M | $9.76M | $10.74M | $10.09M | $8.46M | $7.81M | $8.26M | $7.12M | $6.85M | $6.84M | $5.88M | $5.21M |
| High Forecast | $11.39M | $10.74M | $10.63M | $10.42M | $10.41M | $9.76M | $10.74M | $10.09M | $8.46M | $7.81M | $8.26M | $7.12M | $6.85M | $6.84M | $5.88M | $5.21M |
| Low Forecast | $11.39M | $10.74M | $10.63M | $10.42M | $10.41M | $9.76M | $10.74M | $10.09M | $8.46M | $7.81M | $8.26M | $7.12M | $6.85M | $6.84M | $5.88M | $5.21M |
| Surprise % | - | - | - | - | - | - | 0.32% | - | 0.36% | 0.61% | 0.59% | 0.69% | 0.86% | 0.53% | 0.97% | 0.90% |
Biotricity's average Quarter SG&A projection for Dec 23 is $9.76M, based on 1 Wall Street analysts, with a range of $9.76M to $9.76M. The forecast indicates a 179.92% rise compared to BTCY last annual SG&A of $3.49M (Sep 23).
Biotricity EPS Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | $-0.42 | - | - | $-0.09 | $-0.09 | $-0.09 | $-0.11 | $-0.15 | $-0.27 | $-0.17 |
| Avg Forecast | $-0.11 | $-0.11 | $1.54 | $1.34 | $-0.36 | $-0.44 | $-0.34 | $-0.41 | $-0.54 | $-0.54 | $-0.47 | $-0.66 | $-0.60 | $-0.82 | $-0.84 | $-0.54 |
| High Forecast | $-0.11 | $-0.11 | $1.54 | $1.34 | $-0.36 | $-0.44 | $-0.34 | $-0.41 | $-0.54 | $-0.54 | $-0.47 | $-0.66 | $-0.60 | $-0.82 | $-0.84 | $-0.54 |
| Low Forecast | $-0.11 | $-0.11 | $1.54 | $1.34 | $-0.36 | $-0.44 | $-0.34 | $-0.41 | $-0.54 | $-0.54 | $-0.47 | $-0.66 | $-0.60 | $-0.82 | $-0.84 | $-0.54 |
| Surprise % | - | - | - | - | - | - | 1.24% | - | - | 0.17% | 0.20% | 0.14% | 0.18% | 0.18% | 0.32% | 0.31% |
According to undefined Wall Street analysts, Biotricity's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BTCY previous annual EPS of $NaN (undefined).
Biotricity Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TELA | TELA Bio | $2.90 | $8.00 | 175.86% | Buy |
| BJDX | Bluejay Diagnostics | $3.85 | $10.00 | 159.74% | Buy |
| MXCT | MaxCyte | $4.11 | $8.00 | 94.65% | Buy |
| DCTH | Delcath Systems | $11.89 | $22.00 | 85.03% | Buy |
| NARI | Inari Medical | $51.93 | $65.63 | 26.38% | Buy |
| CVRX | CVRx | $12.77 | $14.25 | 11.59% | Buy |
| SRDX | Surmodics | $39.63 | $39.50 | -0.33% | Buy |
| CLPT | ClearPoint Neuro | $15.49 | $15.00 | -3.16% | Buy |
| HSCS | Heart Test Laboratories | $3.72 | $3.00 | -19.35% | Buy |